Special Issue

Virus-Like Particle Vaccines and Other Vaccine Formulations Against Respiratory Viruses and Protozoan Parasites

Message from the Guest Editor

Respiratory viruses (influenza virus, respiratory syncytial virus) and protozoan parasites (*Plasmodium* spp., *Toxoplasma gondii, Leishmania* spp.) continue to threaten public health worldwide. Although many efforts have been made to develop vaccines, effective vaccines are currently lacking for many of these pathogens. This Special Issue focuses on the development of vaccines based on virus-like particles and other platforms against respiratory viruses and protozoan parasites. We invite the submission of any original research articles and reviews on vaccine studies, and they will be highly appreciated.

Guest Editor

Prof. Dr. Fu-Shi Quan

- 1. Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea
- Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

Deadline for manuscript submissions

closed (30 June 2023)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/140411

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

